Sutro Biopharma Stock Buy Hold or Sell Recommendation
| STRO Stock | USD 0.81 0.44 35.20% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Sutro Biopharma is 'Strong Sell'. The recommendation algorithm takes into account all of Sutro Biopharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out Sutro Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide. In addition, we conduct extensive research on individual companies such as Sutro and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Sutro |
Execute Sutro Biopharma Buy or Sell Advice
The Sutro recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sutro Biopharma. Macroaxis does not own or have any residual interests in Sutro Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sutro Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Sutro Biopharma Trading Alerts and Improvement Suggestions
| Sutro Biopharma generated a negative expected return over the last 90 days | |
| Sutro Biopharma has high historical volatility and very poor performance | |
| Sutro Biopharma has some characteristics of a very speculative penny stock | |
| Sutro Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 62.04 M. Net Loss for the year was (227.46 M) with profit before overhead, payroll, taxes, and interest of 62.04 M. | |
| Sutro Biopharma currently holds about 225.64 M in cash with (191.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sutro Biopharma has a poor financial position based on the latest SEC disclosures | |
| Over 75.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Sutro Biopharma Inc Q4 2024 Earnings Call Highlights Strategic Focus and Financial ... |
Sutro Biopharma Returns Distribution Density
The distribution of Sutro Biopharma's historical returns is an attempt to chart the uncertainty of Sutro Biopharma's future price movements. The chart of the probability distribution of Sutro Biopharma daily returns describes the distribution of returns around its average expected value. We use Sutro Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sutro Biopharma returns is essential to provide solid investment advice for Sutro Biopharma.
| Mean Return | -1.64 | Value At Risk | -10.2 | Potential Upside | 6.40 | Standard Deviation | 6.49 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sutro Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sutro Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Sutro Biopharma, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Sutro Biopharma back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.9 M | Parkman Healthcare Partners Llc | 2024-12-31 | 1.7 M | Goldman Sachs Group Inc | 2024-12-31 | 1.7 M | State Street Corp | 2024-12-31 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.5 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.1 M | Renaissance Technologies Corp | 2024-12-31 | 1 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 859.4 K | Blackrock Inc | 2024-12-31 | 7.6 M | Suvretta Capital Management, Llc | 2024-12-31 | 7.5 M |
Sutro Biopharma Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (1.7M) | (1.3M) | (58K) | (4.5M) | (4.1M) | (3.9M) | |
| Investments | 604K | (82.0M) | (35.0M) | (18.3M) | (16.5M) | (17.3M) | |
| Change In Cash | 202.0M | (175.7M) | 16.8M | 22.0M | 121.0M | 127.1M | |
| Free Cash Flow | (74.9M) | (97.0M) | (4.3M) | (115.9M) | (194.6M) | (184.9M) | |
| Depreciation | 4.3M | 4.8M | 5.7M | 6.8M | 7.2M | 6.0M | |
| Other Non Cash Items | 606K | 6.2M | (13.6M) | (2.2M) | 4.0M | 4.2M | |
| Capital Expenditures | 7.1M | 15.3M | 7.9M | 4.3M | 3.1M | 6.2M | |
| Net Income | (32.1M) | (105.5M) | (119.2M) | (106.8M) | (227.5M) | (216.1M) | |
| End Period Cash Flow | 207.0M | 31.3M | 48.1M | 70.1M | 191.2M | 200.7M | |
| Change To Netincome | 10.7M | (28.5M) | 36.6M | 12.7M | 14.6M | 15.3M |
Sutro Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sutro Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sutro Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sutro stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.62 | |
β | Beta against Dow Jones | 0.34 | |
σ | Overall volatility | 6.33 | |
Ir | Information ratio | -0.24 |
Sutro Biopharma Volatility Alert
Sutro Biopharma is displaying above-average volatility over the selected time horizon. Sutro Biopharma is a potential penny stock. Although Sutro Biopharma may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Sutro Biopharma. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Sutro instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Sutro Biopharma Fundamentals Vs Peers
Comparing Sutro Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sutro Biopharma's direct or indirect competition across all of the common fundamentals between Sutro Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sutro Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sutro Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sutro Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sutro Biopharma to competition |
| Fundamentals | Sutro Biopharma | Peer Average |
| Return On Equity | -2.34 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Operating Margin | (4.41) % | (5.51) % |
| Current Valuation | (225.88 M) | 16.62 B |
| Shares Outstanding | 82.46 M | 571.82 M |
| Shares Owned By Insiders | 4.28 % | 10.09 % |
| Shares Owned By Institutions | 75.17 % | 39.21 % |
| Number Of Shares Shorted | 4.41 M | 4.71 M |
| Price To Earning | 53.08 X | 28.72 X |
| Price To Book | 1.52 X | 9.51 X |
| Price To Sales | 1.08 X | 11.42 X |
| Revenue | 62.04 M | 9.43 B |
| Gross Profit | 62.04 M | 27.38 B |
| EBITDA | (238.45 M) | 3.9 B |
| Net Income | (227.46 M) | 570.98 M |
| Cash And Equivalents | 225.64 M | 2.7 B |
| Cash Per Share | 4.33 X | 5.01 X |
| Total Debt | 23.15 M | 5.32 B |
| Debt To Equity | 0.27 % | 48.70 % |
| Current Ratio | 7.44 X | 2.16 X |
| Book Value Per Share | 0.54 X | 1.93 K |
| Cash Flow From Operations | (191.54 M) | 971.22 M |
| Short Ratio | 4.90 X | 4.00 X |
| Earnings Per Share | (1.55) X | 3.12 X |
| Price To Earnings To Growth | 0.12 X | 4.89 X |
| Target Price | 7.89 | |
| Beta | 1.22 | -0.15 |
| Market Capitalization | 66.8 M | 19.03 B |
| Total Asset | 387.21 M | 29.47 B |
| Retained Earnings | (786.87 M) | 9.33 B |
| Working Capital | 327.8 M | 1.48 B |
| Net Asset | 387.21 M |
Note: Disposition of 18750 shares by Newell William J of Sutro Biopharma subject to Rule 16b-3 [view details]
Sutro Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sutro . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Sutro Biopharma Buy or Sell Advice
When is the right time to buy or sell Sutro Biopharma? Buying financial instruments such as Sutro Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Sutro Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Currency ETFs Thematic Idea Now
Alternative Currency ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Alternative Currency ETFs theme has 55 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Currency ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sutro Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share | Quarterly Revenue Growth (0.87) | Return On Assets | Return On Equity |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.